Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2016 - 2021)

Historic Other Non-Current Liabilities for Protalix BioTherapeutics (PLX) over the last 9 years, with Q2 2021 value amounting to $38000.0.

  • Protalix BioTherapeutics' Other Non-Current Liabilities fell 6935.48% to $38000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $38000.0, marking a year-over-year decrease of 6935.48%. This contributed to the annual value of $51000.0 for FY2020, which is 8998.04% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Other Non-Current Liabilities of $38000.0 as of Q2 2021, which was down 6935.48% from $26000.0 recorded in Q1 2021.
  • In the past 5 years, Protalix BioTherapeutics' Other Non-Current Liabilities ranged from a high of $6.2 million in Q3 2018 and a low of $26000.0 during Q1 2021
  • In the last 5 years, Protalix BioTherapeutics' Other Non-Current Liabilities had a median value of $5.1 million in 2017 and averaged $2.9 million.
  • In the last 5 years, Protalix BioTherapeutics' Other Non-Current Liabilities surged by 1743.78% in 2017 and then tumbled by 9914.37% in 2020.
  • Protalix BioTherapeutics' Other Non-Current Liabilities (Quarter) stood at $5.1 million in 2017, then grew by 4.77% to $5.3 million in 2018, then plummeted by 90.38% to $509000.0 in 2019, then crashed by 89.98% to $51000.0 in 2020, then decreased by 25.49% to $38000.0 in 2021.
  • Its last three reported values are $38000.0 in Q2 2021, $26000.0 for Q1 2021, and $51000.0 during Q4 2020.